Memantine rapidly crosses the blood-brain barrier, can be administered with or without food, and exhibits no pharmacokinetic differences based on age or gender.

The majority of the administered drug is excreted unchanged in the urine; the remainder is excreted as inactive metabolites of the primary drug.

Memantine has no or minimal effects on CYP450 isoenzymes, and no known interactions with donepezil.
Dose reduction in patients with moderate renal impairment should be considered.

In patients with severe renal impairment, the use of memantine has not been systematically evaluated and is not recommended.